异常表达的长非编码 RNA 作为新诊断多发性骨髓瘤潜在的预后生物标志物：系统评价和荟萃分析。

Aberrantly expressed long noncoding RNAs as potential prognostic biomarkers in newly diagnosed multiple myeloma: A systemic review and meta-analysis.

机构信息

Medical College of Nanchang University, Nanchang, Jiangxi, 330006, China.

Department of Hematology, Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, 330006, China.

出版信息

Cancer Med. 2023 Feb;12(3):2199-2218. doi: 10.1002/cam4.5135. Epub 2022 Sep 4.

DOI:10.1002/cam4.5135

PMID:36057947

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9939128/

Abstract

BACKGROUND

Numerous studies have manifested long noncoding RNAs (lncRNAs) as biomarkers to determine the prognosis of multiple myeloma (MM) patients. Nevertheless, the prognostic role of lncRNAs in MM is still ambiguous. Herein, we performed a meta-analysis to evaluate the predictive value of aberrantly expressed lncRNAs in MM.

METHODS

A systemic literature search was performed in PubMed, EMBASE, Cochrane, and Web of Science databases until October 9, 2021, and the protocol was registered in the PROSPERO database (CRD42021284364). Our study extracted the hazard ratios (HRs) and 95% confidence intervals (CIs) of overall survival (OS), progression-free survival (PFS), or event-free survival (EFS). Begg's and Egger's tests were employed to correct publication bias.

RESULT

Twenty-six individual studies containing 3501 MM patients were enrolled in this study. The results showed that aberrant expression of lncRNAs was associated with poor OS and PFS of MM patients. The pooled HRs for univariate OS and PFS were 1.48 (95% CI = 1.17-1.88, p < 0.001) and 1.30 (95% CI = 1.18-1.43, p < 0.001), respectively, whereas the pooled HRs for multivariate OS and PFS were 1.50 (95% CI = 1.16-1.95, p < 0.001) and 1.59 (95% CI = 1.22-2.07, p < 0.001), respectively. Subgroup analysis suggested that MALAT1, TCF7, NEAT1, and PVT1 upregulation were associated with poor OS (p < 0.05), PVT1, and TCF7 upregulation were implicated with worse PFS (p < 0.05), while only TCF7 overexpression was correlated with reduced EFS (p < 0.05). Moreover, the contour-enhanced funnel plot demonstrated the reliability of our current conclusion, which was not affected by publication bias.

CONCLUSION

Aberrantly expressed particular lncRNAs are critical prognostic indicators in long-term survival as well as promising biomarkers in progression-free status. However, different cutoff values and dissimilar methods to assess lncRNA expression among studies may lead to heterogeneity.

摘要

背景

大量研究表明长链非编码 RNA（lncRNAs）可作为标志物，用于判断多发性骨髓瘤（MM）患者的预后。然而，lncRNAs 在 MM 中的预后作用仍存在争议。本研究进行了一项荟萃分析，以评估异常表达的 lncRNAs 在 MM 中的预测价值。

方法

系统检索 PubMed、EMBASE、Cochrane 和 Web of Science 数据库，检索时间截至 2021 年 10 月 9 日，并在 PROSPERO 数据库（CRD42021284364）中注册了方案。本研究提取了总生存期（OS）、无进展生存期（PFS）或无事件生存期（EFS）的风险比（HR）和 95%置信区间（CI）。采用 Begg 和 Egger 检验校正发表偏倚。

结果

共纳入 26 项包含 3501 例 MM 患者的个体研究。结果显示，lncRNAs 的异常表达与 MM 患者的 OS 和 PFS 不良相关。单因素 OS 和 PFS 的汇总 HR 分别为 1.48（95%CI=1.17-1.88，p<0.001）和 1.30（95%CI=1.18-1.43，p<0.001），多因素 OS 和 PFS 的汇总 HR 分别为 1.50（95%CI=1.16-1.95，p<0.001）和 1.59（95%CI=1.22-2.07，p<0.001）。亚组分析表明，MALAT1、TCF7、NEAT1 和 PVT1 上调与 OS 不良相关（p<0.05），PVT1 和 TCF7 上调与 PFS 较差相关（p<0.05），而仅 TCF7 过表达与 EFS 降低相关（p<0.05）。此外，轮廓增强漏斗图表明我们的结论是可靠的，不受发表偏倚的影响。